Safety and Efficacy of Tirofiban after Intravenous Thrombolysis with Urokinase in Patients with Acute Ischemic Stroke

Qu, Dian; Liu, Huanhuan; Wei, Zhongming; Cheng, Yao; Fei, Yutong; Xu, Jinghan; Lv, Xiuyu; Li, Wendi

doi:10.3389/fneur.2025.1529331

ORIGINAL RESEARCH article

Front. Neurol.

Sec. Stroke

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1529331

Safety and Efficacy of Tirofiban after Intravenous Thrombolysis with Urokinase in Patients with Acute Ischemic Stroke

Provisionally accepted

Dian Qu

Huanhuan Liu

Zhongming Wei

Yao Cheng

Yutong Fei

Jinghan Xu

Xiuyu Lv ^*

Wendi Li ^*

Harbin 242 hospital, Harbin, Heilongjiang Province, China

The final, formatted version of the article will be published soon.

Tirofiban combined with alteplase thrombolysis or endovascular therapy has been proven to improve the prognosis of patients with acute ischemic stroke (AIS). Some patients, due to the extended time window beyond 4 hours and economic considerations, opt for urokinase thrombolysis instead of alteplase thrombolysis in China. However, there is currently limited research on the use of urokinase thrombolysis bridged with tirofiban. We employed propensity score match to pair 80 sets of patients from a total of 196 individuals who underwent urokinase thrombolysis for acute ischemic stroke. The study analyzed the 14-day National Institutes of Health Stroke Scale (NIHSS), 90-day modified Rankin Scale (mRS), bleeding events, and compared the odds ratio (OR) of patients with mRS scores of 0-2 within the subgroups. The results show that the NIHSS at 14 days of the tirofiban group was significantly lower than that of the dual antiplatelet group. No significant difference was found in the proportion of patients with mRS Score 0-2. The odds ratios were slightly different in subgroups classified with or without previous stroke and hypertension. It was confirmed that the tirofiban might be safe in AIS patients received tirofiban after urokinase thrombolysis and could improve short-term neurological function.

Keywords: Urokinase, Acute ischemic stroke, Tirofiban, Urokinase thrombolysis, efficacy

Received: 15 Jan 2025; Accepted: 24 Feb 2025.

Copyright: © 2025 Qu, Liu, Wei, Cheng, Fei, Xu, Lv and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xiuyu Lv, Harbin 242 hospital, Harbin, Heilongjiang Province, China
Wendi Li, Harbin 242 hospital, Harbin, Heilongjiang Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.